About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR

Company Statement

Biocon’s Drug Substance Facility in Bangalore completes U.S. FDA Inspection with No observations

Bengaluru, India, September 22, 2018

“This is to inform you that the U.S. FDA conducted a periodic cGMP inspection of our Drug Substance manufacturing site at Bangalore Campus from Sep 17 - 21, 2018. The weeklong audit concluded without any observations and no Form 483 was issued. The successful audit of this site reflects our strong commitment to cGMP compliance.”  -Company Spokesperson


<< Back




Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved